In view of these observations and those detailed above, the mechanisms of IFN-α in melanoma and the possible association with selected parameters of altered immune control suggest that it may be possible to identify underlying tumor or patient factors predictive of benefit prior to initiating therapy and to avoid the toxicities of IFN-α in those predicted to have no benefit. This evidence concerns the gene IFNA1 and melanoma.